Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
58.9M
Short interest
settlement 2026-10-15
4.4
Days to cover
+1.6 days vs prior
39.5%
Short share of volume
2026-10-28
521,568
Fails to deliver
settlement 2026-09-30
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in IOVA is 58,925,298 shares, down 28,202,573 shares over the last month. Over the last 48 readings it ranged from 53,988,814 shares (15 November 2024) to 131,334,639 shares (13 February 2026). The latest reading sits at the bottom of that range. At the reported average volume of 13.3M shares a day that is 4.4 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/iova" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 58,925,298 | -9.1% | 13,310,584 | 4.43 |
| 2026-09-30 | 64,827,030 | -25.6% | 22,908,160 | 2.83 |
| 2026-09-15 | 87,127,871 | -1.1% | 11,730,216 | 7.43 |
| 2026-08-31 | 88,138,991 | -14.4% | 16,696,048 | 5.28 |
| 2026-08-14 | 102,940,590 | +3.0% | 21,509,752 | 4.79 |
| 2026-07-31 | 99,975,709 | +0.1% | 15,923,753 | 6.28 |
| 2026-07-15 | 99,892,938 | -0.6% | 16,903,817 | 5.91 |
| 2026-06-30 | 100,526,623 | -2.9% | 14,159,736 | 7.10 |
| 2026-06-15 | 103,489,642 | -0.7% | 13,107,577 | 7.90 |
| 2026-05-29 | 104,249,751 | -2.2% | 12,722,798 | 8.19 |
| 2026-05-15 | 106,608,353 | -7.1% | 17,782,438 | 6.00 |
| 2026-04-30 | 114,711,667 | +5.4% | 12,535,651 | 9.15 |
| 2026-04-15 | 108,804,045 | -1.8% | 16,639,967 | 6.54 |
| 2026-03-31 | 110,832,243 | -3.7% | 11,697,703 | 9.47 |
| 2026-03-13 | 115,070,206 | -12.1% | 23,097,517 | 4.98 |
| 2026-02-27 | 130,927,595 | -0.3% | 18,040,821 | 7.26 |
| 2026-02-13 | 131,334,639 | +24.8% | 8,986,769 | 14.61 |
| 2026-01-30 | 105,255,004 | -10.1% | 13,899,672 | 7.57 |
| 2026-01-15 | 117,099,153 | -1.7% | 11,562,081 | 10.13 |
| 2025-12-31 | 119,070,866 | -1.1% | 13,446,524 | 8.86 |
| 2025-12-15 | 120,342,810 | +1.2% | 9,501,925 | 12.67 |
| 2025-11-28 | 118,939,462 | +2.8% | 10,055,957 | 11.83 |
| 2025-11-14 | 115,733,068 | +21.3% | 28,665,756 | 4.04 |
| 2025-10-31 | 95,415,882 | +14.1% | 12,863,511 | 7.42 |
| 2025-10-15 | 83,612,571 | +14.6% | 11,319,936 | 7.39 |
| 2025-09-30 | 72,971,971 | +11.1% | 10,139,600 | 7.20 |
| 2025-09-15 | 65,704,715 | -7.9% | 9,311,224 | 7.06 |
| 2025-08-29 | 71,319,978 | -0.1% | 12,497,239 | 5.71 |
| 2025-08-15 | 71,364,792 | +5.4% | 16,989,216 | 4.20 |
| 2025-07-31 | 67,706,980 | -31.4% | 31,867,928 | 2.12 |
| 2025-07-15 | 98,633,209 | +1.9% | 13,682,386 | 7.21 |
| 2025-06-30 | 96,777,448 | +6.4% | 10,660,458 | 9.08 |
| 2025-06-13 | 90,964,131 | +5.3% | 13,019,306 | 6.99 |
| 2025-05-30 | 86,361,273 | +12.1% | 12,171,958 | 7.10 |
| 2025-05-15 | 77,018,516 | +3.3% | 25,407,243 | 3.03 |
| 2025-04-30 | 74,567,033 | +4.5% | 8,321,513 | 8.96 |
| 2025-04-15 | 71,372,146 | -5.1% | 10,833,378 | 6.59 |
| 2025-03-31 | 75,186,511 | +11.7% | 8,044,005 | 9.35 |
| 2025-03-14 | 67,304,707 | +12.9% | 10,982,706 | 6.13 |
| 2025-02-28 | 59,585,491 | -6.3% | 12,772,685 | 4.67 |
| 2025-02-14 | 63,597,563 | -0.5% | 7,298,159 | 8.71 |
| 2025-01-31 | 63,909,963 | +3.1% | 7,900,584 | 8.09 |
| 2025-01-15 | 61,984,016 | +1.1% | 10,543,599 | 5.88 |
| 2024-12-31 | 61,305,700 | +3.3% | 7,114,427 | 8.62 |
| 2024-12-13 | 59,327,307 | +4.2% | 4,518,236 | 13.13 |
| 2024-11-29 | 56,916,236 | +5.4% | 7,552,343 | 7.54 |
| 2024-11-15 | 53,988,814 | -9.6% | 10,246,348 | 5.27 |
| 2024-10-31 | 59,731,383 | -1.0% | 5,180,814 | 11.53 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of IOVA volume is 39.5%, down 0.6 points over the last five sessions. Over the last 30 readings it ranged from 31.7% (7 October 2026) to 48.0% (16 October 2026). The latest reading is in line with the 30-session average of 38.6%, on 3.6M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 1.4M | 3.6M | 39.5% | 12,451 |
| 2026-10-27 | 1.5M | 4.4M | 35.1% | 30,850 |
| 2026-10-26 | 1.3M | 3.7M | 35.4% | 17,937 |
| 2026-10-23 | 1.7M | 4.0M | 41.5% | 11,424 |
| 2026-10-22 | 1.9M | 4.9M | 39.1% | 58,361 |
| 2026-10-21 | 2.5M | 6.2M | 40.1% | 26,886 |
| 2026-10-20 | 1.8M | 4.7M | 38.6% | 31,452 |
| 2026-10-19 | 1.6M | 4.2M | 38.8% | 16,209 |
| 2026-10-16 | 3.0M | 6.4M | 48.0% | 7,655 |
| 2026-10-15 | 1.5M | 4.6M | 31.9% | 6,321 |
| 2026-10-14 | 2.1M | 5.2M | 39.7% | 14,914 |
| 2026-10-13 | 1.7M | 4.6M | 37.8% | 5,695 |
| 2026-10-12 | 1.4M | 3.9M | 35.8% | 19,115 |
| 2026-10-09 | 3.2M | 8.6M | 37.1% | 14,789 |
| 2026-10-08 | 2.4M | 6.2M | 38.2% | 11,144 |
| 2026-10-07 | 2.0M | 6.4M | 31.7% | 40,004 |
| 2026-10-06 | 3.3M | 9.5M | 34.2% | 60,841 |
| 2026-10-05 | 2.0M | 5.7M | 35.3% | 17,716 |
| 2026-10-02 | 2.2M | 5.8M | 37.4% | 1,311 |
| 2026-10-01 | 3.0M | 7.6M | 40.2% | 15,765 |
| 2026-09-30 | 6.0M | 14.1M | 42.7% | 56,604 |
| 2026-09-29 | 19.2M | 45.3M | 42.3% | 281,261 |
| 2026-09-28 | 1.8M | 4.8M | 38.1% | 21,025 |
| 2026-09-25 | 2.2M | 5.8M | 38.1% | 21,808 |
| 2026-09-24 | 2.5M | 5.8M | 42.4% | 39,229 |
| 2026-09-23 | 3.3M | 7.4M | 45.2% | 17,390 |
| 2026-09-22 | 2.7M | 7.2M | 38.1% | 25,270 |
| 2026-09-21 | 2.8M | 6.2M | 45.0% | 27,503 |
| 2026-09-18 | 2.2M | 6.6M | 33.8% | 2,289 |
| 2026-09-17 | 4.5M | 12.3M | 36.3% | 25,277 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in IOVA is 521,568 shares, up 287,469 shares over the last settlement date. Over the last 30 readings it ranged from 265 shares (8 July 2026) to 521,568 shares (30 September 2026). The latest reading sits at the top of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 521,568 | $14.45 | $7.5M |
| 2026-09-29 | 234,099 | $10.99 | $2.6M |
| 2026-09-28 | 1,535 | $11.00 | $17K |
| 2026-09-24 | 3,672 | $10.19 | $37K |
| 2026-09-21 | 3,253 | $10.25 | $33K |
| 2026-09-16 | 43,674 | $9.36 | $409K |
| 2026-09-04 | 1,846 | $8.70 | $16K |
| 2026-08-31 | 9,696 | $8.01 | $78K |
| 2026-08-27 | 528 | $8.08 | $4K |
| 2026-08-25 | 34,408 | $8.06 | $277K |
| 2026-08-24 | 9,917 | $8.29 | $82K |
| 2026-08-21 | 28,340 | $8.99 | $255K |
| 2026-08-18 | 5,100 | $7.10 | $36K |
| 2026-08-17 | 499 | $6.98 | $3K |
| 2026-08-11 | 4,096 | $6.40 | $26K |
| 2026-08-07 | 13,186 | $6.21 | $82K |
| 2026-08-04 | 154,353 | $4.32 | $667K |
| 2026-08-03 | 236,695 | $4.07 | $963K |
| 2026-07-24 | 39,206 | $5.13 | $201K |
| 2026-07-23 | 27,065 | $5.17 | $140K |
| 2026-07-22 | 33,525 | $5.48 | $184K |
| 2026-07-20 | 23,227 | $5.00 | $116K |
| 2026-07-17 | 256,612 | $4.66 | $1.2M |
| 2026-07-14 | 918 | $4.04 | $4K |
| 2026-07-08 | 265 | $4.35 | $1K |
| 2026-07-06 | 29,299 | $4.31 | $126K |
| 2026-06-29 | 380,213 | $4.25 | $1.6M |
| 2026-06-26 | 5,137 | $4.21 | $22K |
| 2026-06-23 | 273,784 | $4.06 | $1.1M |
| 2026-06-22 | 340,285 | $3.91 | $1.3M |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for IOVA in the last 90 days. The most recent filings are listed below. Latest filing: Vogt Frederick G (Interim CEO & General Counsel) on 2026-09-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 7K | $8.70 | $58K | 595K |
| 2026-09-08 | Vogt Frederick G | Interim CEO & General Counsel | Exercise or conversion | 16K | $0.00 | $0 | 602K |
| 2026-09-08 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 4K | $8.70 | $39K | 256K |
| 2026-09-08 | Puri Raj K. | Chief Regulatory Officer | Exercise or conversion | 10K | $0.00 | $0 | 261K |
| 2026-09-08 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 4K | $8.70 | $35K | 142K |
| 2026-09-08 | BILINSKY IGOR | Chief Operating Officer | Exercise or conversion | 8K | $0.00 | $0 | 146K |
| 2026-09-01 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 18K | $8.28 | $147K | 586K |
| 2026-09-01 | Vogt Frederick G | Interim CEO & General Counsel | Exercise or conversion | 42K | $0.00 | $0 | 604K |
| 2026-09-01 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 3K | $8.28 | $21K | 251K |
| 2026-09-01 | Puri Raj K. | Chief Regulatory Officer | Exercise or conversion | 5K | $0.00 | $0 | 254K |
| 2026-09-01 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 4K | $8.28 | $37K | 138K |
| 2026-09-01 | BILINSKY IGOR | Chief Operating Officer | Exercise or conversion | 9K | $0.00 | $0 | 143K |
| 2026-08-10 | Kirby Daniel Gordon | Chief Commercial Officer | Tax withholding | 2K | $6.40 | $16K | 155K |
| 2026-08-10 | Kirby Daniel Gordon | Chief Commercial Officer | Exercise or conversion | 10K | $0.00 | $0 | 157K |
| 2026-08-06 | Roche Corleen M. | Chief Financial Officer | Tax withholding | 21K | $6.21 | $132K | 29K |
| 2026-08-06 | Roche Corleen M. | Chief Financial Officer | Exercise or conversion | 50K | $0.00 | $0 | 50K |
| 2026-06-05 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 7K | $4.23 | $28K | 562K |
| 2026-06-05 | Vogt Frederick G | Interim CEO & General Counsel | Exercise or conversion | 16K | $0.00 | $0 | 569K |
| 2026-06-05 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 4K | $4.23 | $16K | 248K |
| 2026-06-05 | Puri Raj K. | Chief Regulatory Officer | Exercise or conversion | 10K | $0.00 | $0 | 252K |
| 2026-06-05 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Tax withholding | 4K | $4.23 | $17K | 140K |
| 2026-06-05 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Exercise or conversion | 8K | $0.00 | $0 | 144K |
| 2026-06-05 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 4K | $4.23 | $17K | 134K |
| 2026-06-05 | BILINSKY IGOR | Chief Operating Officer | Exercise or conversion | 8K | $0.00 | $0 | 138K |
| 2026-06-01 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 18K | $3.96 | $70K | 554K |
| 2026-06-01 | Vogt Frederick G | Interim CEO & General Counsel | Exercise or conversion | 42K | $0.00 | $0 | 571K |
| 2026-06-01 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 3K | $3.96 | $10K | 242K |
| 2026-06-01 | Puri Raj K. | Chief Regulatory Officer | Exercise or conversion | 5K | $0.00 | $0 | 245K |
| 2026-06-01 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Tax withholding | 4K | $3.96 | $18K | 136K |
| 2026-06-01 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Exercise or conversion | 9K | $0.00 | $0 | 141K |
| 2026-06-01 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 4K | $3.96 | $18K | 130K |
| 2026-06-01 | BILINSKY IGOR | Chief Operating Officer | Exercise or conversion | 9K | $0.00 | $0 | 135K |
| 2026-05-11 | Kirby Daniel Gordon | Chief Commercial Officer | Tax withholding | 2K | $3.70 | $9K | 147K |
| 2026-05-11 | Kirby Daniel Gordon | Chief Commercial Officer | Exercise or conversion | 10K | $0.00 | $0 | 149K |
| 2026-03-05 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 27K | $4.58 | $123K | 530K |
| 2026-03-05 | Vogt Frederick G | Interim CEO & General Counsel | Exercise or conversion | 62K | $0.00 | $0 | 556K |
| 2026-03-05 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 18K | $4.58 | $84K | 239K |
| 2026-03-05 | Puri Raj K. | Chief Regulatory Officer | Exercise or conversion | 39K | $0.00 | $0 | 258K |
| 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Tax withholding | 17K | $4.58 | $76K | 132K |
| 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Exercise or conversion | 31K | $0.00 | $0 | 148K |
| 2026-03-05 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 17K | $4.58 | $76K | 126K |
| 2026-03-05 | BILINSKY IGOR | Chief Operating Officer | Exercise or conversion | 31K | $0.00 | $0 | 142K |
| 2026-03-02 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 23K | $3.79 | $86K | 494K |
| 2026-03-02 | Vogt Frederick G | Interim CEO & General Counsel | Exercise or conversion | 52K | $0.00 | $0 | 517K |
| 2026-03-02 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 3K | $3.79 | $11K | 219K |
| 2026-03-02 | Puri Raj K. | Chief Regulatory Officer | Exercise or conversion | 5K | $0.00 | $0 | 221K |
| 2026-03-02 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Tax withholding | 7K | $3.79 | $27K | 117K |
| 2026-03-02 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Exercise or conversion | 13K | $0.00 | $0 | 124K |
| 2026-03-02 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 7K | $3.79 | $26K | 111K |
| 2026-03-02 | BILINSKY IGOR | Chief Operating Officer | Exercise or conversion | 12K | $0.00 | $0 | 118K |
| 2026-02-24 | Kirby Daniel Gordon | Chief Commercial Officer | Tax withholding | 34K | $3.78 | $129K | 139K |
| 2026-02-24 | Kirby Daniel Gordon | Chief Commercial Officer | Exercise or conversion | 120K | $0.00 | $0 | 174K |
| 2026-02-10 | Kirby Daniel Gordon | Chief Commercial Officer | Tax withholding | 16K | $2.60 | $43K | 54K |
| 2026-02-10 | Kirby Daniel Gordon | Chief Commercial Officer | Exercise or conversion | 40K | $0.00 | $0 | 70K |
| 2025-12-02 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 4K | $2.14 | $9K | 465K |
| 2025-12-02 | Vogt Frederick G | Interim CEO & General Counsel | Exercise or conversion | 10K | $0.00 | $0 | 469K |
| 2025-12-02 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Tax withholding | 2K | $2.14 | $4K | 112K |
| 2025-12-02 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Exercise or conversion | 4K | $0.00 | $0 | 114K |
| 2025-12-02 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 2K | $2.14 | $4K | 106K |
| 2025-12-02 | BILINSKY IGOR | Chief Operating Officer | Exercise or conversion | 4K | $0.00 | $0 | 108K |
| 2025-12-01 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 18K | $2.23 | $39K | 459K |
| 2025-12-01 | Vogt Frederick G | Interim CEO & General Counsel | Exercise or conversion | 42K | $0.00 | $0 | 476K |
| 2025-12-01 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 2K | $2.23 | $6K | 216K |
| 2025-12-01 | Puri Raj K. | Chief Regulatory Officer | Exercise or conversion | 5K | $0.00 | $0 | 218K |
| 2025-12-01 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Tax withholding | 4K | $2.23 | $10K | 110K |
| 2025-12-01 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Exercise or conversion | 9K | $0.00 | $0 | 114K |
| 2025-12-01 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 4K | $2.23 | $10K | 104K |
| 2025-12-01 | BILINSKY IGOR | Chief Operating Officer | Exercise or conversion | 9K | $0.00 | $0 | 108K |
| 2025-09-02 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 22K | $2.19 | $48K | 435K |
| 2025-09-02 | Vogt Frederick G | Interim CEO & General Counsel | Exercise or conversion | 52K | $0.00 | $0 | 457K |
| 2025-09-02 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 2K | $2.19 | $5K | 213K |
| 2025-09-02 | Puri Raj K. | Chief Regulatory Officer | Exercise or conversion | 5K | $0.00 | $0 | 215K |
| 2025-09-02 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Tax withholding | 6K | $2.19 | $14K | 105K |
| 2025-09-02 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Exercise or conversion | 13K | $0.00 | $0 | 112K |
| 2025-09-02 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 6K | $2.19 | $14K | 100K |
| 2025-09-02 | BILINSKY IGOR | Chief Operating Officer | Exercise or conversion | 12K | $0.00 | $0 | 106K |
| 2025-06-05 | Kirby Daniel Gordon | Chief Commercial Officer | Buy | 30K | $1.84 | $55K | 30K |
| 2025-06-02 | Bellemin Jean-Marc | Chief Financial Officer | Exercise or conversion | 9K | $0.00 | $0 | 65K |
| 2025-06-02 | Bellemin Jean-Marc | Chief Financial Officer | Tax withholding | 4K | $1.76 | $8K | 61K |
| 2025-06-02 | BILINSKY IGOR | Chief Operating Officer | Exercise or conversion | 12K | $0.00 | $0 | 100K |
| 2025-06-02 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 6K | $1.76 | $11K | 94K |
| 2025-06-02 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Tax withholding | 6K | $1.76 | $11K | 99K |
| 2025-06-02 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Exercise or conversion | 13K | $0.00 | $0 | 106K |
| 2025-06-02 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 22K | $1.76 | $39K | 405K |
| 2025-06-02 | Vogt Frederick G | Interim CEO & General Counsel | Exercise or conversion | 52K | $0.00 | $0 | 427K |
| 2025-06-02 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 2K | $1.76 | $4K | 210K |
| 2025-06-02 | Puri Raj K. | Chief Regulatory Officer | Exercise or conversion | 5K | $0.00 | $0 | 212K |
| 2025-05-23 | Puri Raj K. | Chief Regulatory Officer | Buy | 6K | $1.74 | $10K | 207K |
| 2025-05-14 | Vogt Frederick G | Interim CEO & General Counsel | Buy | 25K | $1.69 | $42K | 375K |
| 2025-03-14 | Puri Raj K. | Chief Regulatory Officer | Exercise or conversion | 8K | $0.00 | $0 | 204K |
| 2025-03-14 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 3K | $3.59 | $9K | 201K |
| 2025-03-03 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Tax withholding | 33K | $4.04 | $135K | 93K |
| 2025-03-03 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Exercise or conversion | 62K | $0.00 | $0 | 126K |
| 2025-03-03 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 20K | $4.04 | $81K | 195K |
| 2025-03-03 | Puri Raj K. | Chief Regulatory Officer | Exercise or conversion | 60K | $0.00 | $0 | 215K |
| 2025-03-03 | Vogt Frederick G | Interim CEO & General Counsel | Exercise or conversion | 224K | $0.00 | $0 | 445K |
| 2025-03-03 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 95K | $4.04 | $385K | 350K |
| 2025-03-03 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 33K | $4.04 | $135K | 88K |
| 2025-03-03 | BILINSKY IGOR | Chief Operating Officer | Exercise or conversion | 62K | $0.00 | $0 | 121K |
| 2025-03-03 | Bellemin Jean-Marc | Chief Financial Officer | Exercise or conversion | 59K | $0.00 | $0 | 88K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of IOVA in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 7.5% of the class (33,366,587 shares), filed 2026-07-28 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 24.5M | 5.5% | 2026-06-30 |
| 2026-07-28 | 13G/Ano. 3 | BlackRock, Inc.parent holding company | 33.4M | 7.5% | 2026-06-30 |
| 2026-03-27 | 13G/Ano. 6 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding IOVA at their latest 13F. JSON5 of the 30 tracked managers held IOVA at their latest 13F, $148.3M in total at quarter-end prices. Two Sigma Investments is the largest at $79.1M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 19.0M | $79.1M | 0.06% | +5.3M |
| Millennium Management | 2026-06-30 | 8.5M | $35.5M | 0.01% | -888K |
| AQR Capital Management | 2026-06-30 | 3.9M | $16.1M | 0.01% | +3.2M |
| D. E. Shaw & Co. | 2026-06-30 | 2.1M | $8.9M | 0.00% | -5.9M |
| Citadel Advisors | 2026-06-30 | 2.1M | $8.8M | 0.00% | -506K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Iovance Biotherapeutics reported revenue of $99.3M, up 65.7% from the same quarter a year earlier, and net loss of $47.3M (-0.11 diluted EPS). In FY 2025 it generated -$302.4M of operating cash flow.
- Cash
- $110.8M
- Equity
- $736.0M
- Total assets
- $915.5M
- Shares outstanding
- 452,971,432
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $99.3M | -$47.3M | -47.6% | -0.11 |
| Q1 FY 2026 | 2026-03-31 | $71.4M | -$79.0M | -110.7% | -0.19 |
| Q4 FY 2025derived | 2025-12-31 | $86.8M | -$71.9M | -82.9% | n/a |
| Q3 FY 2025 | 2025-09-30 | $67.5M | -$91.3M | -135.3% | -0.25 |
| Q2 FY 2025 | 2025-06-30 | $60.0M | -$111.7M | -186.2% | -0.33 |
| Q1 FY 2025 | 2025-03-31 | $49.3M | -$116.2M | -235.5% | -0.36 |
| Q4 FY 2024derived | 2024-12-31 | $73.7M | -$78.6M | -106.6% | n/a |
| Q3 FY 2024 | 2024-09-30 | $58.6M | -$83.5M | -142.7% | -0.28 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $263.5M | -$391.0M | -$302.4M | $33.8M | n/a | n/a |
| FY 2024 | 2024-12-31 | $164.1M | -$372.2M | -$353.0M | $11.1M | n/a | n/a |
| FY 2023 | 2023-12-31 | $1.2M | -$444.0M | -$361.8M | $22.3M | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | -$395.9M | -$292.8M | $20.4M | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$342.3M | -$227.9M | $37.6M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-29 from the cover page.
What this page is
Iovance Biotherapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Iovance Biotherapeutics (IOVA), SEC CIK 1425205, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 1425205Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
Datasets
Frequently Asked Questions
How much of IOVA is sold short?
58,925,298 shares were held short at the 2026-10-15 settlement, 4.4 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is IOVA's daily short volume?
On 2026-10-28, 1,439,924 of the 3,643,173 IOVA shares reported to FINRA were sold short, 39.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does IOVA have fails to deliver?
The SEC's latest file shows 521,568 IOVA shares failed to deliver at settlement 2026-09-30. Fails are reported per settlement date and published twice a month with a lag.
Are IOVA insiders buying or selling?
No open-market insider trades were reported for IOVA in the last 90 days. The most recent filings are listed below. Latest filing: Vogt Frederick G (Interim CEO & General Counsel) on 2026-09-08.
Who owns 5% or more of IOVA?
2 holders report 5% or more of IOVA in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 7.5% of the class (33,366,587 shares), filed 2026-07-28 for an event on 2026-06-30.
What did IOVA report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Iovance Biotherapeutics reported revenue of $99.3M, up 65.7% from the same quarter a year earlier, and net loss of $47.3M (-0.11 diluted EPS). In FY 2025 it generated -$302.4M of operating cash flow.
Which tracked 13F managers own IOVA?
5 of the 30 tracked 13F managers held IOVA shares at their latest filing, $148.3M in all. The largest: Two Sigma Investments (19.0M shares, $79.1M), Izzy Englander's Millennium Management (8.5M shares, $35.5M), Cliff Asness's AQR Capital Management (3.9M shares, $16.1M), D. E. Shaw & Co. (2.1M shares, $8.9M), Ken Griffin's Citadel Advisors (2.1M shares, $8.8M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.